{
  "docId": "019de515-bf16-778d-9d2b-a6c6e17ebc6c",
  "docSlug": "7a45cce2c7eb1605e2a52f1d1ebe6b6d",
  "documentTitle": "MaxCyte | Investor Presentation Deck | 20 slides",
  "authorId": "maxcyte",
  "authorName": "MaxCyte",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 20,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "business_model",
  "function": "present_framework",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de515-bf16-778d-9d2b-a6c6e17ebc6c/10",
  "deckHref": "/decks/019de515-bf16-778d-9d2b-a6c6e17ebc6c",
  "deckJsonHref": "/decks/019de515-bf16-778d-9d2b-a6c6e17ebc6c.json",
  "deckAnchorHref": "/decks/019de515-bf16-778d-9d2b-a6c6e17ebc6c#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.52,
        "w": 0.299,
        "x": 0.638,
        "y": 0.313
      },
      "kind": "diagram",
      "text": "MaxCyte Revenue Model\nAnnual instrument license fee****\nSingle-use disposables\n(processing assemblies)\nStrategic partnership terms\nRazor/razor blade economics and share of\ntherapeutic economics",
      "attrs": {},
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45619df5-1e4b-4ac9-a0f9-87ee5af27606",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.448,
        "w": 0.165,
        "x": 0.264,
        "y": 0.313
      },
      "kind": "diagram",
      "text": "MaxCyte Revenue Model\nInstrument sale***\nSingle-use disposables\n(processing assemblies)\nRazor/razor blade economics",
      "attrs": {},
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d4aabc15-e500-49a6-baf8-7adb099fcf41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.155,
        "x": 0.805,
        "y": 0.055
      },
      "kind": "image",
      "text": "MaxCyte",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "504af584-5867-4131-9372-1ef0df6a23ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.29,
        "w": 0.305,
        "x": 0.075,
        "y": 0.45
      },
      "kind": "image",
      "text": "ATX\nST",
      "attrs": {},
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "279b4903-1257-41e9-a9c1-4c90410c914f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.29,
        "w": 0.29,
        "x": 0.49,
        "y": 0.45
      },
      "kind": "image",
      "text": "GTX",
      "attrs": {},
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d979ddb8-1bcd-444e-94c8-e577f4607f15",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.36,
        "x": 0.071,
        "y": 0.144
      },
      "kind": "list",
      "text": "DRUG DISCOVERY & DEVELOPMENT -\nCells to Discover Drugs\nBlue-chip client base includes the top ten global pharma\ncompanies and 20 of the top 25**",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23fddc61-4cba-455b-be1d-c597d00287ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.458,
        "x": 0.502,
        "y": 0.144
      },
      "kind": "list",
      "text": "CELL THERAPY - Cells as Drugs\n19 SPL partnerships with cell therapy developers that allow for more\nthan 125 clinical programs*; > $1.55B in potential pre-commercial\nmilestones*",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a92302d6-c57d-4eed-994a-cde7ea74774e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.015,
        "w": 0.018,
        "x": 0.49,
        "y": 0.962
      },
      "kind": "other",
      "text": "10",
      "attrs": {},
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40bc5512-cfaa-4014-a27d-74994dd6bef3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.36,
        "x": 0.037,
        "y": 0.853
      },
      "kind": "source-note",
      "text": "* Updated as of December 2022\n** Based on 2021 revenue\n*** Includes RUO-non-exclusive license only; $119,000 list price for STx sale\n**** Lease price of $150,000 per year for pre-clinical use or $250,000 per year for clinical use",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04655739-2dfb-4fb7-9cbd-a49fcff57493",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.015,
        "w": 0.159,
        "x": 0.82,
        "y": 0.962
      },
      "kind": "source-note",
      "text": "© 2023 MaxCyte, Inc. All Rights Reserved",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1a13f42-49ea-47a5-9218-76fba6c68973",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.539,
        "x": 0.041,
        "y": 0.06
      },
      "kind": "title",
      "text": "Growing Opportunity from R&D to Therapeutics",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c9a186b-26c8-4df9-a368-d75cd646d1d9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 15,
      "from": 8,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1b37bf2a-4731-4886-81e1-dbaaf7521786",
      "evidence": "The deck presents the benefits of MaxCyte's technology and the limitations of current methods.",
      "position": 0,
      "objective": "What are the consequences of not adopting MaxCyte's technology?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 13,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "aef0ad90-31bd-4c88-a7ab-1edcbad173d9",
      "evidence": "The deck presents information on SPL partnerships and revenue potential.",
      "position": 1,
      "objective": "What are the potential revenue upsides from SPL partnerships?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}